Back to top
more

BeiGene (BGNE)

(Delayed Data from NSDQ)

$206.82 USD

206.82
127,491

+4.09 (2.02%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $206.96 +0.14 (0.07%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

Why Earnings Season Could Be Great for BeiGene (BGNE)

by Zacks Equity Research

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week

by Nalak Das

Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.

BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study

by Zacks Equity Research

BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.

Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer

by Zacks Equity Research

Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

by Ekta Bagri

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

by Zacks Equity Research

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review

by Zacks Equity Research

Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

by Zacks Equity Research

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

by Zacks Equity Research

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion

by Zacks Equity Research

The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.

Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

by Zacks Equity Research

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

by Zacks Equity Research

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

by Zacks Equity Research

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

by Zacks Equity Research

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

by Zacks Equity Research

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy

by Zacks Equity Research

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Indrajit Bandyopadhyay headshot

4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

by Indrajit Bandyopadhyay

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

BeiGene's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in BeiGene.

Amgen's New Kyprolis Combo Gets FDA Nod for Multiple Myeloma

by Zacks Equity Research

Amgen's (AMGN) Kyprolis gets FDA approval for label expansion as second to fourth-line treatment for relapsed/refractory multiple myeloma in combination with J&J's Darzalex and dexamethasone.

What Makes BeiGene, Ltd. (BGNE) a New Buy Stock

by Zacks Equity Research

BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.